Dr Laharie and colleagues aimed to identify predictive factors of response to infliximab in luminal Crohn's disease.
The research team included all consecutive patients with luminal Crohn’s disease treated with infliximab between October 1999 and March 2003 in Bordeaux's referral centers.
All had at least 3 months follow-up post infliximab infusion and no prior treatment with infliximab.
The researchers determined response rates 2 and 8 weeks after infusion according to Crohn's Disease Activity Index, whereby remission equals less than 150 and response is more than 100.
The team reported that among 44 patients (33 female and mean age 34 years), 39 (88%) had a clinical response 2 weeks after infusion (79% in remission).
| The only factor associated with response duration was initiating immunosuppressive therapy in women|
| Gastroenterologie Clinique et Biologique|
The investigators noted that at week 8, the rate of response was 61% and exclusive colonic involvement predicted sustained response to treatment.
The probability of remission at 56 weeks was 21%.
The investigative team demonstrated with multivariate analysis that the only factor associated with response duration was initiating immunosuppressive therapy in women.
Dr Laharie concludes, “Exclusive colonic involvement is the only predictive factor of sustained response to infliximab in luminal Crohn’s disease.”
“At the time of infliximab infusion, initiation or modification of immunosuppressive therapy may favor sustained response, at least in women.